soul trial oral semaglutide cardiovascular outcomes nejm 2025 results and in Obesity without Diabetes Semaglutide cardiovascular outcomes align more

The committee concluded that the current evidence called for further action, including updated consumer and clinical safety warnings

This program does not only include a prescription for Ozempic but nutritional and workout programs to guide patients through their weight loss journey

Equity is eroding even as markets expand

GLP-1 RA Addition to Background Insulin The combination of a GLP-1 RA with basal insulin is commonly used in patients with T2D and is a recommended combination in major treatment guidelines to meet individualized treatment goals in appropriate patients

GLP-1, a key hormone, communicates between the gut and brain to manage digestion and blood sugar levels while supporting heart, liver, and kidney health